Sachin Jain
Stock Analyst at Bank of America Securities
(2.97)
# 2,605
Out of 4,408 analysts
256
Total ratings
53.4%
Success rate
2.1%
Average return
Main Sectors:
Stocks Rated by Sachin Jain
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVS Novartis AG | Maintained: Buy | $176 | $153.07 | +14.77% | 3 | Jun 11, 2026 | |
| SWX: NOVN Novartis AG | Maintained: Buy | CHF 140.00 | $122.08 | +14.68% | 25 | Jun 11, 2026 | |
| LON: AZN AstraZeneca PLC | Reiterated: Buy | 16,500p | $13,462.00 | +22.57% | 78 | Jun 9, 2026 | |
| LON: GSK GSK plc | Reiterated: Hold | 2,350p | $1,984.00 | +18.45% | 13 | Jun 9, 2026 | |
| EPA: SAN Sanofi | Reiterated: Hold | €92.00 | $76.59 | +20.12% | 19 | Apr 23, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Hold | kr 340.00 → kr 350.00 | $283.55 | +23.43% | 27 | Feb 5, 2026 | |
| ETR: BAYN Bayer Aktiengesellschaft | Maintained: Buy | €30.00 → €35.00 | $36.19 | -3.29% | 9 | Dec 2, 2025 | |
| LON: 0MGB Genmab A/S | Maintained: Buy | kr 1,950 → kr 2,250 | $1,617.64 | +39.09% | 23 | Nov 25, 2025 | |
| BME: GRF Grifols, S.A. | Maintained: Buy | €10.60 | $9.03 | +17.33% | 1 | Nov 25, 2025 | |
| GSK GSK plc | Reiterated: Sell | $48 → $23 | $53.04 | -57.02% | 4 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $141 → $58 | $43.88 | +32.27% | 37 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | CHF 275.00 → CHF 340.00 | $330.00 | n/a | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €110.00 → €205.00 | $133.25 | n/a | 3 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 → $49 | $25.06 | n/a | 4 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $24 | $23.80 | n/a | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $195 | $49.91 | n/a | 1 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 | $26.21 | n/a | 1 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $170.28 | n/a | 1 | May 2, 2016 |
Novartis AG
Jun 11, 2026
Maintained: Buy
Price Target: $176
Current: $153.07
Upside: +14.77%
Novartis AG
Jun 11, 2026
Maintained: Buy
Price Target: CHF 140.00
Current: $122.08
Upside: +14.68%
AstraZeneca PLC
Jun 9, 2026
Reiterated: Buy
Price Target: 16,500p
Current: $13,462.00
Upside: +22.57%
GSK plc
Jun 9, 2026
Reiterated: Hold
Price Target: 2,350p
Current: $1,984.00
Upside: +18.45%
Sanofi
Apr 23, 2026
Reiterated: Hold
Price Target: €92.00
Current: $76.59
Upside: +20.12%
Novo Nordisk A/S
Feb 5, 2026
Maintained: Hold
Price Target: kr 340.00 → kr 350.00
Current: $283.55
Upside: +23.43%
Bayer Aktiengesellschaft
Dec 2, 2025
Maintained: Buy
Price Target: €30.00 → €35.00
Current: $36.19
Upside: -3.29%
Genmab A/S
Nov 25, 2025
Maintained: Buy
Price Target: kr 1,950 → kr 2,250
Current: $1,617.64
Upside: +39.09%
Grifols, S.A.
Nov 25, 2025
Maintained: Buy
Price Target: €10.60
Current: $9.03
Upside: +17.33%
GSK plc
Oct 29, 2025
Reiterated: Sell
Price Target: $48 → $23
Current: $53.04
Upside: -57.02%
Oct 9, 2025
Maintained: Hold
Price Target: $141 → $58
Current: $43.88
Upside: +32.27%
Sep 13, 2024
Upgraded: Buy
Price Target: CHF 275.00 → CHF 340.00
Current: $330.00
Upside: n/a
Jun 12, 2023
Maintained: Buy
Price Target: €110.00 → €205.00
Current: $133.25
Upside: n/a
May 11, 2023
Reiterated: Buy
Price Target: $48 → $49
Current: $25.06
Upside: n/a
Feb 2, 2023
Maintained: Hold
Price Target: $24
Current: $23.80
Upside: n/a
Jan 17, 2023
Maintained: Hold
Price Target: $195
Current: $49.91
Upside: n/a
Nov 1, 2022
Maintained: Buy
Price Target: $60
Current: $26.21
Upside: n/a
May 2, 2016
Maintained: Buy
Price Target: n/a
Current: $170.28
Upside: n/a